Related Experiment Video
Updated: Feb 2, 2026

Techniques to Induce and Quantify Cellular Senescence
Published on: May 1, 2017
New KAT6 inhibitors induce senescence and arrest cancer growth
1School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, China.
Abstract:
Lysine acetyltransferases (KATs) catalyze lysine acetylation, a reversible protein modification implicated in a wide variety of disease states. Histone acetyltransferases (HATs) comprise a KAT sub-class that acetylate specific lysines in histones, hence playing an important role in the regulation of chromatin organization and function. HATs are critical regulators of signaling in many diseases, including cancer. KAT6A (also known as monocytic leukemia zinc finger protein, MOZ) and KAT6B (also known as MORF and QKF) belong to the MYST family of HATs, that comprise KAT5-KAT8. They are the targets of chromosomal translocations identified in acute myeloid leukaemia and various cancers. It seems logical therefore that inhibition of KAT6A and KAT6B may provide a therapeutic benefit in cancer. Baell et al. discovered a new class of anti-cancer drug that can put cancer cells into a permanent sleep or senescence, using high-throughput screening followed by medicinal chemistry optimization, in-cell assays, biochemical assessment of target engagement, and tumour models in mice and fish. This research showed promise in arresting tumour growth in pre-clinical models of blood and liver cancers as well as delaying or stopping relapse without damaging the cells' DNA or some harmful side-effects caused by chemotherapy and radiotherapy.
Insights
Researchers identified a novel anti-cancer drug that induces cancer cell senescence, halting tumor growth in preclinical models. This approach offers a promising alternative to chemotherapy, avoiding DNA damage and side effects.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Lysine acetyltransferases (KATs) regulate protein acetylation, a key modification in disease.
- Histone acetyltransferases (HATs), a KAT subclass, are crucial for chromatin regulation and implicated in various cancers.
- KAT6A and KAT6B are MYST family HATs targeted in chromosomal translocations in leukemia and other cancers.
Purpose of the Study:
- To discover and develop novel anti-cancer therapeutics targeting KAT6A and KAT6B.
- To evaluate the efficacy of a new class of drugs in inducing cancer cell senescence and arresting tumor growth.
Main Methods:
- High-throughput screening and medicinal chemistry optimization.
- In-cell assays and biochemical assessment of target engagement.
- Preclinical testing in mouse and fish tumor models.
Main Results:
- Discovery of a new class of anti-cancer drugs inducing cancer cell senescence.
- Demonstrated promise in arresting tumor growth in preclinical models of blood and liver cancers.
- Showed potential to delay or stop relapse without DNA damage or chemotherapy-like side effects.
Conclusions:
- Inhibition of KAT6A and KAT6B presents a viable therapeutic strategy for cancer treatment.
- The newly discovered drugs offer a novel approach to cancer therapy by inducing senescence.
- This research highlights a promising, less toxic alternative to traditional cancer treatments.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Replicative Cell Senescence
Mechanisms of Retrovirus-induced Cancers
Population Growth
Meristems and Plant Growth
Dipeptidyl Peptidase 4 Inhibitors

